Pictet Asset Management Holding SA Has $96.96 Million Position in BridgeBio Pharma, Inc. $BBIO

Key Points

• Pictet Asset Management increased its stake in BridgeBio by 12.1% in Q4 to 1,270,290 shares, a position worth about $96.96 million (roughly 0.66% of the company), signaling continued institutional interest.
• Wall Street is broadly bullish — 24 Buy vs. 1 Sell rating, a consensus "Moderate Buy" and an average price target of $87.38, with several firms (Truist, Morgan Stanley, JPMorgan, Wells Fargo) recently raising targets.
• Company catalysts are mixed: BridgeBio settled the Pfizer Vyndamax patent dispute (a de‑risking event), but it missed Q2 EPS estimates (‑$1.00 vs. ‑$0.75) while beating revenue at $154.18 million (up 2521% YoY), prompting uneven market reaction.

Pictet Asset Management Holding SA raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 12.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,270,290 shares of the company's stock after acquiring an additional 136,939 shares during the period. Pictet Asset Management Holding SA owned about 0.66% of BridgeBio Pharma worth $96,956,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in BridgeBio Pharma by 2.1% in the third quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company's stock valued at $874,257,000 after acquiring an additional 347,074 shares during the period. Farallon Capital Management LLC grew its position in BridgeBio Pharma by 3.7% in the third quarter. Farallon Capital Management LLC now owns 8,192,000 shares of the company's stock valued at $425,492,000 after acquiring an additional 292,000 shares during the period. Aisling Capital Management LP grew its position in BridgeBio Pharma by 0.4% in the third quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company's stock valued at $316,294,000 after acquiring an additional 21,486 shares during the period. Invesco Ltd. grew its position in BridgeBio Pharma by 40.3% in the third quarter. Invesco Ltd. now owns 3,928,657 shares of the company's stock valued at $204,054,000 after acquiring an additional 1,127,592 shares during the period. Finally, Franklin Resources Inc. grew its position in BridgeBio Pharma by 75.8% in the third quarter. Franklin Resources Inc. now owns 1,444,023 shares of the company's stock valued at $75,003,000 after acquiring an additional 622,618 shares during the period. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Mizuho reaffirmed an "outperform" rating and set a $106 price target, signaling analyst conviction and a sizable upside vs. the current level; this supports buyer interest. Mizuho Outperform / $106 PT
• Positive Sentiment: HC Wainwright reiterated a "buy" rating with a $100 price target, another bullish analyst endorsement that can underpin the stock. HC Wainwright Buy / $100 PT
• Positive Sentiment: BridgeBio announced a settlement with Pfizer in the Vyndamax patent dispute — removing litigation uncertainty could be a material de‑risking event, though market reaction has been mixed. BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)
• Neutral Sentiment: BridgeBio posted its Q2 2025 earnings transcript — contains operational and management commentary investors will parse for guidance and program updates; read for specifics on sales and R&D cadence. BridgeBio (BBIO) Q2 2025 Earnings Transcript
• Neutral Sentiment: BridgeBio launched a health education campaign featuring high‑profile advocates (Morgan Freeman, Howard H. White) — positive PR but unlikely to move valuation materially in the short term. BridgeBio Launches Health Education Effort
• Neutral Sentiment: Market commentary asking whether it's "too late" to buy after a one‑year surge — useful framing for investors assessing momentum and valuation, but not news that directly alters fundamentals. Is It Too Late To Consider BridgeBio Pharma (BBIO)?
• Negative Sentiment: A headline ties BBIO to a Pfizer connection while noting the stock is on track for its worst day in months — negative headlines and headline volatility can prompt sell pressure even if underlying news is mixed. BBIO on track for worst day in 2.5 months
• Negative Sentiment: A Zacks preview warns BridgeBio lacks the setup for an earnings beat this quarter — expectations of another negative EPS print or guidance misses can pressure the stock. Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings?

Wall Street Analyst Weigh In

A number of analysts have weighed in on BBIO shares. Truist Financial upped their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Morgan Stanley upped their price target on BridgeBio Pharma from $96.00 to $98.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. TD Cowen reiterated a "buy" rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. JPMorgan Chase & Co. upped their price target on BridgeBio Pharma from $89.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday, March 10th. Finally, Wells Fargo & Company upped their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the company an "overweight" rating in a research report on Friday, February 13th. Twenty-four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $87.38.

Insiders Place Their Bets

In other BridgeBio Pharma news, Director Andrea Ellis sold 64,921 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the transaction, the director owned 18,589 shares of the company's stock, valued at approximately $1,205,868.43. This represents a 77.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Maricel Apuli sold 510 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares in the company, valued at approximately $9,210,352.95. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 237,084 shares of company stock valued at $16,634,419 over the last quarter. Company insiders own 18.20% of the company's stock.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $69.75 on Wednesday. The stock's fifty day moving average is $71.33 and its 200-day moving average is $70.84. The stock has a market capitalization of $13.66 billion, a PE ratio of -18.45 and a beta of 1.09. BridgeBio Pharma, Inc. has a 52 week low of $31.77 and a 52 week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. The business's revenue was up 2521.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.40) EPS. As a group, analysts forecast that BridgeBio Pharma, Inc. will post -2.07 earnings per share for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.